Anyone taking the job if it were offered to them?

Quote
Anonymous said:
You are right, I got my offer call on Friday night after their meeting in Philly. Not at all what I thought so I am just going to stay at current company. I did tell Pat that I wish him the best.
Click to expand...

The money wasn't what they initially promised? Or did you think they would up the offer after the final.... Did all the offers from last week go out already?
 












Anonymous said:
Didn't someone say they got 106? Just spill it- how much was your offer?
Click to expand...

Managers have been instructed that they can go as high as 110k max. If they however do this with a specific rep....then money will be deducted from other team members. It is that simple. They get a certain amount and have to distribute it appropriately. In rare instances someone may be able to negotiate higher, but then other reps salaries will have to be lowered in order to adjust. Think very carefully before going onboard.
 






Anonymous said:
Managers have been instructed that they can go as high as 110k max. If they however do this with a specific rep....then money will be deducted from other team members. It is that simple. They get a certain amount and have to distribute it appropriately. In rare instances someone may be able to negotiate higher, but then other reps salaries will have to be lowered in order to adjust. Think very carefully before going onboard.
Click to expand...


Seems like you know more than what has been on the boards. Please explain what are the things we need to think carefully?
 
























Anonymous said:
I might go if they loosen up the wallet and pay for the "top talent" they say they want. Maybe they will negotiate with more stock or sign on bonus. not sure about any of that though. No use talking about it anyway unless an offer comes. I think I will get it, just not sure if it will be enough.
Click to expand...

You obviously are not a candidate because there is a sign on bonus.
 


















This makes me think about it more. Could be just lawyers drumming up business, but could also be something to it. Don't know. Press release today:

Robbins Umeda LLP Announces an Investigation of Chelsea Therapeutics International, Ltd.

SAN DIEGO, Mar 15, 2012 (BUSINESS WIRE) -- Shareholder rights firm Robbins Umeda LLP announces an investigation into Chelsea Therapeutics International, Ltd. /quotes/zigman/97770/quotes/nls/chtp CHTP +2.56% . Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Gregory E. Del Gaizo at (800) 350-6003, inquiry@robbinsumeda.com, or via the shareholder information form on the firm's website.

Robbins Umeda LLP is investigating whether officers or directors at Chelsea Therapeutics issued materially false and misleading statements to investors that were designed to deceive the market and artificially inflate the company's stock price. In particular, the firm is examining allegations that senior officials at Chelsea Therapeutics misled investors by failing to accurately disclose material information about the commercial viability, effectiveness, and market potential for NORTHERA, an experimental drug developed by the company for the treatment of neurogenic disorders like Parkinson's disease.

Presently, the U.S. Food and Drug Administration (the "FDA") is reviewing Chelsea Therapeutics' New Drug Application for NORTHERA. On February 13, 2012, Chelsea Therapeutics issued a press release that revealed that the company received an FDA briefing document that outlined concerns related to the agency's risk-benefit analysis for NORTHERA. According to the company's press release, the FDA highlighted concerns related to "the short duration of our clinical studies [and] the limited size of our study population given the orphan indication and the challenges in quantifying symptomatic and clinical benefit."

Since these facts have emerged, shares of Chelsea Therapeutics have lost over 38% of their value. After recently trading as high as $5.20 per share on February 8, 2012, shares of Chelsea Therapeutics' common stock closed on February 13, 2012, at just $3.11 per share.

Robbins Umeda LLP highlights that one option available to Chelsea Therapeutics' shareholders is filing a class action lawsuit on behalf of investors to recover damages incurred as a result of the wrongdoing.

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com .
 






Anonymous said:
This makes me think about it more. Could be just lawyers drumming up business, but could also be something to it. Don't know. Press release today:

Robbins Umeda LLP Announces an Investigation of Chelsea Therapeutics International, Ltd.

SAN DIEGO, Mar 15, 2012 (BUSINESS WIRE) -- Shareholder rights firm Robbins Umeda LLP announces an investigation into Chelsea Therapeutics International, Ltd. /quotes/zigman/97770/quotes/nls/chtp CHTP +2.56% . Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Gregory E. Del Gaizo at (800) 350-6003, inquiry@robbinsumeda.com, or via the shareholder information form on the firm's website.

Robbins Umeda LLP is investigating whether officers or directors at Chelsea Therapeutics issued materially false and misleading statements to investors that were designed to deceive the market and artificially inflate the company's stock price. In particular, the firm is examining allegations that senior officials at Chelsea Therapeutics misled investors by failing to accurately disclose material information about the commercial viability, effectiveness, and market potential for NORTHERA, an experimental drug developed by the company for the treatment of neurogenic disorders like Parkinson's disease.

Presently, the U.S. Food and Drug Administration (the "FDA") is reviewing Chelsea Therapeutics' New Drug Application for NORTHERA. On February 13, 2012, Chelsea Therapeutics issued a press release that revealed that the company received an FDA briefing document that outlined concerns related to the agency's risk-benefit analysis for NORTHERA. According to the company's press release, the FDA highlighted concerns related to "the short duration of our clinical studies [and] the limited size of our study population given the orphan indication and the challenges in quantifying symptomatic and clinical benefit."

Since these facts have emerged, shares of Chelsea Therapeutics have lost over 38% of their value. After recently trading as high as $5.20 per share on February 8, 2012, shares of Chelsea Therapeutics' common stock closed on February 13, 2012, at just $3.11 per share.

Robbins Umeda LLP highlights that one option available to Chelsea Therapeutics' shareholders is filing a class action lawsuit on behalf of investors to recover damages incurred as a result of the wrongdoing.

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com .
Click to expand...

This crap happens all the time. They throw it at the wall and see what sticks.
 






Thanks for sending. Another huge red flag. Everyone needs to takes these red flags seriously before taking the job.



Anonymous said:
This makes me think about it more. Could be just lawyers drumming up business, but could also be something to it. Don't know. Press release today:

Robbins Umeda LLP Announces an Investigation of Chelsea Therapeutics International, Ltd.

SAN DIEGO, Mar 15, 2012 (BUSINESS WIRE) -- Shareholder rights firm Robbins Umeda LLP announces an investigation into Chelsea Therapeutics International, Ltd. /quotes/zigman/97770/quotes/nls/chtp CHTP +2.56% . Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Gregory E. Del Gaizo at (800) 350-6003, inquiry@robbinsumeda.com, or via the shareholder information form on the firm's website.

Robbins Umeda LLP is investigating whether officers or directors at Chelsea Therapeutics issued materially false and misleading statements to investors that were designed to deceive the market and artificially inflate the company's stock price. In particular, the firm is examining allegations that senior officials at Chelsea Therapeutics misled investors by failing to accurately disclose material information about the commercial viability, effectiveness, and market potential for NORTHERA, an experimental drug developed by the company for the treatment of neurogenic disorders like Parkinson's disease.

Presently, the U.S. Food and Drug Administration (the "FDA") is reviewing Chelsea Therapeutics' New Drug Application for NORTHERA. On February 13, 2012, Chelsea Therapeutics issued a press release that revealed that the company received an FDA briefing document that outlined concerns related to the agency's risk-benefit analysis for NORTHERA. According to the company's press release, the FDA highlighted concerns related to "the short duration of our clinical studies [and] the limited size of our study population given the orphan indication and the challenges in quantifying symptomatic and clinical benefit."

Since these facts have emerged, shares of Chelsea Therapeutics have lost over 38% of their value. After recently trading as high as $5.20 per share on February 8, 2012, shares of Chelsea Therapeutics' common stock closed on February 13, 2012, at just $3.11 per share.

Robbins Umeda LLP highlights that one option available to Chelsea Therapeutics' shareholders is filing a class action lawsuit on behalf of investors to recover damages incurred as a result of the wrongdoing.

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com .
Click to expand...
 






Anonymous said:
Thanks for sending. Another huge red flag. Everyone needs to takes these red flags seriously before taking the job.
Click to expand...

actually this isn't a red-flag so much as it is a indication of how many ambulance-chasing law firms there are out there. It is my understanding that the clinical studies undertaken by Chelsea were based on suggestions from the FDA and what they wanted to see. So for a law firm to suggest that Chelsea "misled" investors is kind of a red herring, given that they did what was suggested by the FDA, and the FDA, in the advisory board, suggested that the data didn't show what they wanted to see.
 






Anonymous said:
actually this isn't a red-flag so much as it is a indication of how many ambulance-chasing law firms there are out there. It is my understanding that the clinical studies undertaken by Chelsea were based on suggestions from the FDA and what they wanted to see. So for a law firm to suggest that Chelsea "misled" investors is kind of a red herring, given that they did what was suggested by the FDA, and the FDA, in the advisory board, suggested that the data didn't show what they wanted to see.
Click to expand...

Then go for the job!! No one is stopping you. I will tell you however, most of the top picks have backed out as this opportunity isn't as great as they would like everyone to believe....keep trying to convince yourself
 






The people that will take these jobs will be the ones that haven't done their homework or people that have been displaced and need a job!


Anonymous said:
Then go for the job!! No one is stopping you. I will tell you however, most of the top picks have backed out as this opportunity isn't as great as they would like everyone to believe....keep trying to convince yourself
Click to expand...
 






Keep trying to convince people not to take the job you want..... Are you really that insecure and trying to make this job seem bad, just so you can have it? I'm on to you!

I will gladly accept this job when offered, and keep my fingers crossed that Northera is approved at the end of the month.
 






I'm not saying Northera will not get approved but it will be a LONG road. If you've ever been with a start up company you know they are hiring way to many reps for an orphan drug and reimbursement will be an issue. I personally will not be accepting my offer. It will be interesting to check back here about 6 months after approval. Good luck though...

Anonymous said:
Keep trying to convince people not to take the job you want..... Are you really that insecure and trying to make this job seem bad, just so you can have it? I'm on to you!

I will gladly accept this job when offered, and keep my fingers crossed that Northera is approved at the end of the month.
Click to expand...
 






Anonymous said:
Keep trying to convince people not to take the job you want..... Are you really that insecure and trying to make this job seem bad, just so you can have it? I'm on to you!

I will gladly accept this job when offered, and keep my fingers crossed that Northera is approved at the end of the month.
Click to expand...

I am sincerely no longer interested in the job....truly. No one is on to anyone....your decision and I hope it is the right one for you.
 






Anonymous said:
Then go for the job!! No one is stopping you. I will tell you however, most of the top picks have backed out as this opportunity isn't as great as they would like everyone to believe....keep trying to convince yourself
Click to expand...

not sure why some people are so adamant about worrying about whether other will take a job here or not, but that has no bearing on what I said about the law firm and their tactics. I hypothesize that those doing it are those that have not been called back for an interview. just my .02
 






Top Bottom
Back
Quote